Eesti - eesti - Ravimiamet

orion corporation - pregabaliin - kõvakapsel - 225mg 84tk; 225mg 98tk; 225mg 14tk; 225mg 112tk; 225mg 28tk; 225mg 21tk; 225mg 60tk; 225mg 70tk

Eesti - eesti - Ravimiamet

orion corporation - pregabaliin - kõvakapsel - 100mg 14tk; 100mg 84tk; 100mg 100tk; 100mg 21tk; 100mg 70tk; 100mg 56tk; 100mg 98tk; 100mg 112tk; 100mg 60tk; 100mg 28tk

Eesti - eesti - Ravimiamet

orion corporation - pregabaliin - kõvakapsel - 150mg 56tk; 150mg 112tk; 150mg 100tk; 150mg 14tk; 150mg 98tk; 150mg 21tk; 150mg 60tk; 150mg 28tk

Eesti - eesti - Ravimiamet

orion corporation - pregabaliin - kõvakapsel - 75mg 60tk; 75mg 98tk; 75mg 56tk; 75mg 70tk; 75mg 28tk; 75mg 112tk; 75mg 100tk; 75mg 84tk; 75mg 14tk

Eesti - eesti - Ravimiamet

orion corporation - pregabaliin - kõvakapsel - 300mg 70tk; 300mg 14tk; 300mg 56tk; 300mg 28tk; 300mg 98tk; 300mg 60tk; 300mg 21tk; 300mg 84tk

Eesti - eesti - Ravimiamet

orion corporation - pregabaliin - kõvakapsel - 50mg 28tk; 50mg 84tk; 50mg 70tk; 50mg 98tk; 50mg 14tk; 50mg 112tk; 50mg 60tk; 50mg 21tk; 50mg 100tk; 50mg 56tk

Eesti - eesti - Ravimiamet

orion corporation - pregabaliin - kõvakapsel - 25mg 28tk; 25mg 70tk; 25mg 98tk; 25mg 56tk; 25mg 21tk; 25mg 84tk; 25mg 60tk; 25mg 14tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

orion corporation - dexmedetomidine hydrochloride - närvisüsteem, teised uinutid ja rahustid - koerad - koertega seotud müraga ägeda ärevuse ja hirmu leevendamine.

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vokanamet on näidustatud täiskasvanutel vanuses 18 aastat ja vanemad, tüüp 2 diabeet lisandina toitumise ja treeningu parandamiseks glycaemic hõlma järgmist:patsientidel ei ole piisavalt ohjatud nende maksimaalselt lubatud annustes metformiin alonein patsientidele nende maksimaalselt lubatud annustes metformiin koos teiste glükoosi langetavaid ravimeid, sh insuliini, kui need ei taga piisavat kontrolli glycaemic. patsientidel, juba ravitakse kombinatsioon canagliflozin ja metformiin, nagu eraldi tabletsfor uuringu tulemuste suhtes kombinatsiooni teraapia, mõju glycaemic kontrolli ja kardiovaskulaarsete sündmuste ja elanikkonna uuritud, vt punktid 4. 4, 4. 5 ja 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroksabaan - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombootilised ained - täiskasvanud patsientidel, kellele tehti plaaniline puusa- või põlveliigese asendamise operatsiooni venoosse trombemboolia (vte) ennetamine. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 haemodynamically ebastabiilne pe patsientidel). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 ja 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.